Funding for this research was provided by:
F. Hoffmann-La Roche
Received: 17 June 2022
Accepted: 13 December 2022
First Online: 21 December 2022
: The Ethics Committee of the University of Heidelberg approved this retrospective study and waived the need for consent to participate (S-318/2013), and the standards of the Declaration of Helsinki were followed.
: Not applicable.
: TSP reports consulting fees from Boehringer Ingelheim and Galapagos. JW reports payment or honoraria for lectures and presentations from Boehringer Ingelheim, Roche and MSD; and support for attending meetings and/or travel from Boehringer Ingelheim and Roche. EB reports payment or honoraria for lectures, presentations, speaker bureaus, manuscript writing or educational events from Boehringer Ingelheim, Novartis, and AstraZeneca; support for attending meetings and/or travel from Boehringer Ingelheim and Roche; and participation on a Data Safety Monitoring Board or Advisory Board for Boehringer Ingelheim, Roche and Abbvie. MK reports support for the present manuscript from Roche (made to the institution); grants or contracts from Roche, Galapagos, and Boehringer Ingelheim; consulting fees from Roche, Boehringer Ingelheim, and Galapagos; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Boehringer Ingelheim; Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid in the European Respiratory Society. The other authors have nothing to disclose.